# AURORAX-0093A: Glycosaminoglycan Profiling for Prognostication of Muscle-invasive Bladder Cancer - a Pilot Study

> **NCT05028660** · — · COMPLETED · sponsor: **Elypta** · enrollment: 43 (actual)

## Conditions studied

- Muscle-Invasive Bladder Carcinoma

## Interventions

- **DIAGNOSTIC_TEST:** GAG score

## Key facts

- **NCT ID:** NCT05028660
- **Lead sponsor:** Elypta
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2021-07-21
- **Primary completion:** 2025-04-30
- **Final completion:** 2025-04-30
- **Target enrollment:** 43 (ACTUAL)
- **Last updated:** 2025-05-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05028660

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05028660, "AURORAX-0093A: Glycosaminoglycan Profiling for Prognostication of Muscle-invasive Bladder Cancer - a Pilot Study". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT05028660. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*